Curative Cash Conversion Cycle from 2010 to 2026
| CUBT Stock | USD 0.01 0.0007 11.29% |
Cash Conversion Cycle | First Reported 2010-12-31 | Previous Quarter -14.7 K | Current Value -15.4 K | Quarterly Volatility 109.6 K |
Check Curative Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Curative Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 111.3 K, Interest Expense of 1.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 55.01, Dividend Yield of 0.0 or Days Sales Outstanding of 267. Curative financial statements analysis is a perfect complement when working with Curative Biotechnology Valuation or Volatility modules.
Curative | Cash Conversion Cycle | Build AI portfolio with Curative Stock |
The evolution of Cash Conversion Cycle for Curative Biotechnology provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Curative Biotechnology compares to historical norms and industry peers.
Latest Curative Biotechnology's Cash Conversion Cycle Growth Pattern
Below is the plot of the Cash Conversion Cycle of Curative Biotechnology over the last few years. It is Curative Biotechnology's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Curative Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Cash Conversion Cycle | 10 Years Trend |
|
Cash Conversion Cycle |
| Timeline |
Curative Cash Conversion Cycle Regression Statistics
| Arithmetic Mean | (49,120) | |
| Coefficient Of Variation | (223.23) | |
| Mean Deviation | 59,927 | |
| Median | (14,701) | |
| Standard Deviation | 109,649 | |
| Sample Variance | 12B | |
| Range | 448.3K | |
| R-Value | (0.02) | |
| Mean Square Error | 12.8B | |
| R-Squared | 0.0003 | |
| Significance | 0.95 | |
| Slope | (354.98) | |
| Total Sum of Squares | 192.4B |
Curative Cash Conversion Cycle History
About Curative Biotechnology Financial Statements
Curative Biotechnology shareholders use historical fundamental indicators, such as Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although Curative Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Curative Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Curative Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash Conversion Cycle | -14.7 K | -15.4 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.